Engineering T cell receptor fusion proteins using nonviral CRISPR/Cas9 genome editing for cancer immunotherapy

Abstract

Abstract Manufacture of chimeric antigen receptor (CAR)‐T cells usually involves the use of viral delivery systems to achieve high transgene expression. However, it can be costly and may result in random integration of the CAR into the genome, creating several disadvantages including variation in transgene expression, functional gene silencing and potential oncogenic transformation. Here, we optimized the method of nonviral, CRISPR/Cas9 genome editing using large donor DNA delivery, knocked‐in an anti‐tumor single chain variable fragment (scFv) into the N‐terminus of CD3ε and efficiently generated fusion protein (FP) T cells. These cells displayed FP integration within the TCR/CD3 complex, lower variability in gene expression compared to CAR‐T cells and good cell expansion after transfection. CD3ε FP T cells were predominantly CD8+ effector memory T cells, and exhibited anti‐tumor activity in vitro and in vivo. Dual targeting FP T cells were also generated through the incorporation of scFvs into other CD3 subunits and CD28. Compared to viral‐based methods, this method serves as an alternative and versatile way of generating T cells with tumor‐targeting receptors for cancer immunotherapy.

Keywords

• CAR‐T
• CRISPR/Cas9
• fusion protein
• immunotherapy
• nonviral